XML 65 R27.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Financial Statements Schedule I | 12 Months Ended
--- | ---
Dec. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract] |
Financial Statements Schedule I | Additional financial information of parent company - Financial statements schedule I Zai Lab Limited Financial information of parent company Condensed balance sheets (In U.S. dollars ("$") except for number of shares)
|  | As of December 31, |
|  | 2016 |  |  | 2017 |
|  | $ |  |  | $ |
Assets |  |  |  |  |  |  |  |
Current assets: |  |  |  |  |  |  |  |
Cash and cash equivalents |  |  | 24,813,050 |  |  |  | 181,910,618 |
Prepayments and other current assets |  |  | — |  |  |  | 450,333 |
Total current assets |  |  | 24,813,050 |  |  |  | 182,360,951 |
Investment in subsidiaries |  |  | 62,042,345 |  |  |  | 54,885,326 |
Total assets |  |  | 86,855,395 |  |  |  | 237,246,277 |
Liabilities, mezzanine equity and shareholders' deficits |  |  |  |  |  |  |  |
Liabilities |  |  |  |  |  |  |  |
Current liabilities: |  |  |  |  |  |  |  |
Warrant liabilities |  |  | 3,900,000 |  |  |  | — |
Other payables |  |  | — |  |  |  | 593,317 |
Total current liabilities |  |  | 3,900,000 |  |  |  | 593,317 |
Deferred income |  |  | — |  |  |  | 1,482,000 |
Total liabilities |  |  | 3,900,000 |  |  |  | 2,075,317 |
Mezzanine equity |  |  |  |  |  |  |  |
Series A1 convertible preferred shares (par value US$0.00006 per share; 8,466,667 shares authorized, 8,466,665 shares issued and outstanding as of December 31, 2016) |  |  | 10,028,572 |  |  |  | — |
Series A2 convertible preferred shares (par value US$0.00006 per share; 8,904,032 shares authorized, 8,442,221 shares issued and outstanding as of December 31, 2016) |  |  | 18,278,572 |  |  |  | — |
Series B1 convertible preferred shares (par value US$0.00006 per share; 5,562,337 shares authorized, 5,562,335 shares issued and outstanding as of December 31, 2016) |  |  | 53,100,000 |  |  |  | — |
Series B2 convertible preferred shares (par value US$0.00006 per share; 3,973,098 shares authorized, 3,973,096 shares issued and outstanding as of December 31, 2016) |  |  | 53,100,000 |  |  |  | — |
Total mezzanine equity |  |  | 134,507,144 |  |  |  | — |
Shareholders' (deficit) equity |  |  |  |  |  |  |  |
Ordinary shares (par value of US$0.00006 per share; 83,333,333 shares authorized, 9,657,175 and 49,912,570 shares outstanding as of December 31, 2016 and 2017, respectively) |  |  | 579 |  |  |  | 2,995 |
Subscription receivable |  |  | (5 | ) |  |  | (18 | )
Additional paid-in capital |  |  | 9,313,646 |  |  |  | 345,269,688 |
Accumulated deficit |  |  | (60,167,437 | ) |  |  | (110,551,613 | )
Additional other comprehensive (loss) income |  |  | (698,532 | ) |  |  | 449,908 |
Total shareholders' (deficit) equity |  |  | (51,551,749 | ) |  |  | 235,170,960 |
Total liabilities, mezzanine equity and shareholders' (deficit) equity |  |  | 86,855,395 |  |  |  | 237,246,277 |
Additional financial information of parent company - Financial statements schedule I Zai Lab Limited Financial information of parent company Condensed statements of operations and comprehensive loss (In U.S. dollars ("$") except for number of shares)
|  | Year Ended December 31, |
|  | 2015 |  |  | 2016 |  |  | 2017 |
|  | $ |  |  | $ |  |  | $ |
Operating Expenses: |  |  |  |  |  |  |  |  |  |  |  |
General and administrative |  |  | (56,806 | ) |  |  | (534,660 | ) |  |  | (4,114,144 | )
Loss from operations |  |  | (56,806 | ) |  |  | (534,660 | ) |  |  | (4,114,144 | )
Interest income |  |  | — |  |  |  | — |  |  |  | 50,060 |
Changes in fair value of warrants |  |  | (1,980,000 | ) |  |  | (1,920,000 | ) |  |  | 200,000 |
Equity in loss of subsidiaries |  |  | (15,984,931 | ) |  |  | (35,057,552 | ) |  |  | (46,598,092 | )
Other income |  |  | — |  |  |  | — |  |  |  | 78,000 |
Loss before income tax |  |  | (18,021,737 | ) |  |  | (37,512,212 | ) |  |  | (50,384,176 | )
Income tax expense |  |  | — |  |  |  | — |  |  |  | — |
Net loss attributable to ordinary shareholders |  |  | (18,021,737 | ) |  |  | (37,512,212 | ) |  |  | (50,384,176 | )
Net loss |  |  | (18,021,737 | ) |  |  | (37,512,212 | ) |  |  | (50,384,176 | )
Other comprehensive (loss) income, net of tax of nil: |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency translation adjustment |  |  | (98,893 | ) |  |  | (594,912 | ) |  |  | 1,148,440 |
Comprehensive loss |  |  | (18,120,630 | ) |  |  | (38,107,124 | ) |  |  | (49,235,736 | )
Additional financial information of parent company - Financial statements schedule I Zai Lab Limited Financial information of parent company Condensed statements of cash flows (In U.S. dollars ("$") except for number of shares)
|  | Year Ended December 31, |
|  | 2015 |  |  | 2016 |  |  | 2017 |
|  | $ |  |  | $ |  |  | $ |
Cash flows from Operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  |  | (18,021,737 | ) |  |  | (37,512,212 | ) |  |  | (50,384,176 | )
Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |  |  |  |  |  |  |  |  |  |
Share based compensation |  |  | 56,806 |  |  |  | 534,660 |  |  |  | 3,346,039 |
Change of fair value of warrants |  |  | 1,980,000 |  |  |  | 1,920,000 |  |  |  | (200,000 | )
Equity in loss of subsidiaries |  |  | 15,984,931 |  |  |  | 35,057,552 |  |  |  | 46,598,092 |
Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |  |  |  |
Prepayments and other current assets |  |  | — |  |  |  | — |  |  |  | (450,333 | )
Other payables |  |  | — |  |  |  | — |  |  |  | 553,317 |
Deferred income |  |  | — |  |  |  | — |  |  |  | 1,482,000 |
Net cash provided by operating activities |  |  | — |  |  |  | — |  |  |  | 944,939 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |  |
Investment in subsidiaries |  |  | (21,500,000 | ) |  |  | (84,501,020 | ) |  |  | (31,707,566 | )
Net cash used in investing activities |  |  | (21,500,000 | ) |  |  | (84,501,020 | ) |  |  | (31,707,566 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |  |
Proceed from issuance of convertible preferred shares, net of issuance cost |  |  | 18,278,572 |  |  |  | 106,200,000 |  |  |  | 29,100,000 |
Proceeds from exercise of warrants |  |  | — |  |  |  | — |  |  |  | 1,000,000 |
Proceeds from exercises of stock options |  |  | — |  |  |  | — |  |  |  | 65,500 |
Proceeds from issuance of ordinary shares upon initial public offering |  |  | — |  |  |  | — |  |  |  | 160,424,994 |
Payment of initial public offering costs |  |  | — |  |  |  | — |  |  |  | (2,730,299 | )
Net cash provided by financing activities |  |  | 18,278,572 |  |  |  | 106,200,000 |  |  |  | 187,860,195 |
Effect of foreign exchange rate changes on cash and cash equivalent |  |  | — |  |  |  | — |  |  |  | — |
Net (decrease) increases in cash and cash equivalents |  |  | (3,221,428 | ) |  |  | 21,698,980 |  |  |  | 157,097,568 |
Cash and cash equivalents-beginning of the year |  |  | 6,335,498 |  |  |  | 3,114,070 |  |  |  | 24,813,050 |
Cash and cash equivalents-end of the year |  |  | 3,114,070 |  |  |  | 24,813,050 |  |  |  | 181,910,618 |
Additional financial information of parent company - Financial statements schedule I Zai Lab Limited Financial information of parent company Notes to schedule I (In U.S. dollars ("$") except for number of shares) 1. Schedule I has been provided pursuant to the requirements of Rule 12-04(a) and 5-04(c) of Regulation S-X, which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year. 2. The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the equity method has been used to account for investments in its subsidiaries. For the parent company, the Company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method and Joint Ventures. Such investments are presented on the Condensed Balance Sheets as ‘‘Investment in subsidiaries’’. Ordinarily under the equity, an investor in an equity method investee would cease to recognize its share of the losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses. 3. As of December 31, 2016 and 2017, there were no material contingencies, significant provisions of long term obligations, mandatory dividend or redemption requirements of redeemable stocks or guarantees of the Company.

X
- References No definition available. + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.7-05(c)(Schedule II)) -URI http://asc.fasb.org/extlink&oid=6879921&loc=d3e569147-122900 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=96868048&loc=d3e5283-111683 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 2 -Subparagraph (SX 210.9-06) -URI http://asc.fasb.org/extlink&oid=6882215&loc=d3e537971-122884 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 10 -Section S99 -Paragraph 6 -Subparagraph (SX 210.5-04(c)(Schedule I)) -URI http://asc.fasb.org/extlink&oid=27047687&loc=d3e5864-122674 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690 + Details
Name: | us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration